Crispr Therapeutics shares tumble after significant earnings miss
Freshpet Inc (NASDAQ:FRPT). stock has reached a new 52-week low, trading at 66.69 USD. This marks a significant downturn for the company, which has seen its stock price decline by 44.05% over the past year. According to InvestingPro data, the company’s market capitalization stands at $3.29 billion, with a notably high beta of 1.79 indicating above-average market volatility. The pet food company, known for its fresh, refrigerated meals for pets, has faced challenges in maintaining its stock value amidst fluctuating market conditions and competitive pressures. This 52-week low underscores the volatility and challenges Freshpet is currently navigating in the market. Despite these challenges, InvestingPro analysis shows strong revenue growth of 23.24% and a healthy current ratio of 4.91, suggesting solid financial fundamentals. For deeper insights into Freshpet’s valuation and growth prospects, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Freshpet is preparing to release its second-quarter earnings report, with UBS maintaining a Sell rating and a $65 price target on the company. UBS anticipates that Freshpet will deliver results that align with expectations but notes a slightly negative risk-reward outlook. Meanwhile, Freshpet shareholders have approved all proposals at the company’s 2025 annual meeting, electing all director nominees to the board. UBS also initiated coverage of Freshpet with a Sell rating, citing concerns about overly optimistic growth expectations. Stifel, on the other hand, resumed coverage with a Buy rating, setting a $90 price target and highlighting potential for improved sales growth in late 2025 despite current challenges. TD Cowen downgraded Freshpet from Buy to Hold, setting a $96 price target due to concerns about slowing retail sales growth. TD Cowen also noted the potential influence of activist investor JANA’s push for a sale, though they remain cautious about the likelihood of an immediate buyout.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.